- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04281979
Effects of a Specific Substance in Smokers
February 6, 2023 updated by: Angelica Morales, Oregon Health and Science University
An MRI Study of Neural Activity Following Exposure to a Specific Substance in Young Cigarette Smokers
Although rates of cigarette use are declining, the proportion of nondaily smokers is rising, particularly among young adults.
Among young adults, nondaily smoking is associated with negative health consequences and, for some, may lead to the establishment of life-long smoking patterns.
The goal of this project is to understand the behavioral, psychological and neurobiological factors that contribute to cigarette use in nondaily smokers to aid the development of tailored evidence-based interventions.
Study Overview
Detailed Description
The purpose of this study is to investigate the neurobiological mechanisms associated with cigarette use in young nondaily smokers (ages 21-25).
Nondaily smokers experience fewer symptoms of cigarette withdrawal than daily smokers; however, they still experience difficulty quitting.
Since smoking cessation before the age of 30 substantially attenuates the long-term health consequences associated with smoking, understanding the factors that motivate cigarette use in young nondaily smokers and developing tailored interventions will be critical for curbing cigarette use and improving public health.
The proposed project will use functional magnetic resonance imaging (fMRI) to examine how other substances (e.g.
stimulates, sedatives, or analgesics) impact brain function and will assess the extent to which substance-induced changes in brain function correlate with impulsive choice, cigarette craving, and craving regulation in young adults.
Furthermore, the investigators will assess how substance-induced changes in brain function, impulsivity, craving, and capacity for craving regulation predict cigarette use over the course of 1 year.
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Oregon Health and Science University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 40 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants must be 21-40 years old
- Right-handed
- Fluent in English
- Report smoking cigarettes or e-cigarettes 1-27 days in the past month
- Report binge drinking based on NIAAA criteria (5 or more drinks per occasion for males, 4 or more drinks per occasion for females) at least 1 time in the past 90 days without adverse incident
Exclusion Criteria:
- Seeking treatment for substance use (e.g. nicotine or alcohol use)
- Moderate or Severe Nicotine Dependence
- Current alcohol use disorder
- Illicit substance use other than marijuana use in the past year
- Marijuana use more than 10 times in the past year
- Major neurological or medical illness - Significant head trauma - Current use of medication affecting the central nervous system
- MRI contraindications (e.g. irremovable metal on the body or pregnancy)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
In the placebo conditions participants will consume beverages and capsules that contain no or very small quantities of the study agent.
|
EXPERIMENTAL: Study Agent
|
The study agent will be administered via beverages and/or a capsule.
The substances used in the study are legal, non-prescription, and are proven safe for human consumption at the doses used.
The study agent may be a depressant (such as alcohol), a stimulant (such as caffeine), or an analgesic (such as aspirin).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impulsivity
Time Frame: Immediately after beverage/capsule consumption
|
Impulsivity will be measured by assessing behavior on a temporal discounting task.
|
Immediately after beverage/capsule consumption
|
Resting State Functional Connectivity
Time Frame: 35 minutes after beverage/capsule consumption
|
Brain function will be measured while participants are resting using functional magnetic resonance imaging
|
35 minutes after beverage/capsule consumption
|
Cigarette Craving and Associated Brain Activation
Time Frame: 50 minutes after beverage/capsule consumption
|
Brain function will be measured using functional magnetic resonance imaging while participants complete a Craving Regulation Task
|
50 minutes after beverage/capsule consumption
|
Symptoms of Cigarette Dependence
Time Frame: 1 year follow-up from baseline
|
The Fagerström Test of Nicotine Dependence total score will be used to measure changes in cigarette dependence
|
1 year follow-up from baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 25, 2020
Primary Completion (ANTICIPATED)
March 31, 2024
Study Completion (ANTICIPATED)
March 31, 2024
Study Registration Dates
First Submitted
February 7, 2020
First Submitted That Met QC Criteria
February 21, 2020
First Posted (ACTUAL)
February 24, 2020
Study Record Updates
Last Update Posted (ACTUAL)
February 8, 2023
Last Update Submitted That Met QC Criteria
February 6, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- STUDY00018483
- K01DA046649 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified data will be made available to users
IPD Sharing Time Frame
After data are published
IPD Sharing Access Criteria
Data Use Agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to deleting the data after analyses are completed.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
University of VirginiaRecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking, Cigarette | Quitting SmokingUnited States
-
Columbia UniversityNational Cancer Institute (NCI)RecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking BehaviorsUnited States
-
National Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Cigarette Smoking | Tobacco, SmokingUnited States
-
University GhentRecruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Maastricht University Medical CenterThe Investigative Desk; SEO Amsterdam Economics; IVO Research InstituteEnrolling by invitationSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsNetherlands
-
Jennifer Marler, MDCompletedSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsUnited States
-
Medical University of South CarolinaRecruitingSmoking | Smoking Cessation | Tobacco Smoking | Cigarette SmokingUnited States
-
Ghana Health ServicesKwame Nkrumah University of Science and TechnologyNot yet recruitingSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking Behaviors
Clinical Trials on Study Agent
-
University of FloridaNational Heart, Lung, and Blood Institute (NHLBI)CompletedPompe DiseaseUnited States
-
Seoul National University Bundang HospitalCompletedChronic Renal Insufficiency | Coronary AngiographyKorea, Republic of
-
Basilea PharmaceuticaSidney Kimmel Comprehensive Cancer Center at Johns HopkinsTerminatedGlioblastoma | MGMT-Unmethylated GlioblastomaUnited States
-
Medical College of WisconsinRecruiting
-
Hacettepe UniversityNot yet recruitingDental Caries on Pit and Fissure Surface
-
MiNK TherapeuticsCompletedRespiratory Distress Syndrome, AdultUnited States
-
Lundquist Institute for Biomedical Innovation at...General ElectricCompletedContrast Enhancement on Cardiac CTUnited States
-
Erasmus Medical CenterNot yet recruitingSolid Tumor, AdultNetherlands
-
University of AlbertaGambro Renal Products, Inc.CompletedKidney Failure, AcuteCanada
-
IRCCS Policlinico S. DonatoCompletedAbdominal Aortic AneurismItaly